Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial

被引:44
作者
Witkiewitz, Katie [1 ]
Falk, Daniel E. [2 ]
Litten, Raye Z. [2 ]
Hasin, Deborah S. [3 ]
Kranzler, Henry R. [4 ]
Mann, Karl F. [5 ]
O'Malley, Stephanie S. [6 ]
Anton, Raymond F. [7 ]
机构
[1] Univ New Mexico, Dept Psychol, MSC 03-2220, Albuquerque, NM 87131 USA
[2] NIAAA, Bethesda, MD USA
[3] Columbia Univ, Dept Epidemiol, New York, NY USA
[4] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
[5] Heidelberg Univ, Cent Inst Mental Hlth, Med Fac Mannheim, Mannheim, Germany
[6] Yale Sch Med, New Haven, CT USA
[7] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA
关键词
World Health Organization Risk Drinking Levels; Alcohol Use Disorder; Reduced Alcohol Consumption; Alcohol Treatment Outcomes; Low-Risk Drinking; Alcohol Dependence; MISSING DATA; MODERATE DRINKING; DEPENDENCE; TRAJECTORIES; ACCEPTANCE; PREDICTOR; OUTCOMES; GOALS;
D O I
10.1111/acer.14018
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
BackgroundReductions in the World Health Organization (WHO) risk drinking levels have been proposed as an alternative primary outcome for alcohol clinical trials. Yet, little is known about whether reductions in WHO risk drinking levels can be maintained over time. The current study examined whether reductions in WHO risk drinking levels were maintained for up to 1year following treatment, and whether reductions over time were associated with improvements in functioning. MethodsSecondary data analysis of individuals with alcohol dependence (n=1,226) enrolled in the COMBINE study, a multisite, randomized, placebo-controlled clinical trial. Logistic regression was used to examine the maintenance of end-of-treatment WHO risk level reductions and WHO risk level reductions at the 1-year follow-up. Repeated-measures mixed models were used to examine the association between WHO risk level reductions and functional outcomes over time. ResultsAchieving at least a 1- or 2-level reduction in risk by the end of treatment was significantly associated with WHO risk level reductions at the 1-year follow-up assessment (p<0.001). Among individuals who achieved at least a 1-level reduction by the end of treatment, 85.5% reported at least a 1-level reduction at the 1-year follow-up. Among individuals who achieved at least a 2-level reduction by the end of treatment, 77.8% reported at least a 2-level reduction at the 1-year follow-up. WHO risk level reductions were associated with significantly lower alcohol consumption, better physical health (p<0.01), and fewer alcohol-related consequences (p<0.001) up to 1year following treatment. ConclusionsOne- and 2-level reductions in WHO risk levels during alcohol treatment were maintained after treatment and associated with better functioning over time. These findings support the use of the WHO risk level reductions as an outcome measure that reflects clinically significant improvement in how individuals seeking treatment for alcohol use disorder feel and function.
引用
收藏
页码:979 / 987
页数:9
相关论文
共 42 条
[1]  
American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, DOI DOI 10.1176/APPI.BOOKS.9780890425596
[2]  
[Anonymous], 2010, Guideline on the development of medicinal products for the treatment of alcohol dependence
[3]  
[Anonymous], 2000, International Guide for Monitoring Alcohol Consumption and Related Harm
[4]  
[Anonymous], 2005, HELP PAT WHO DRINK T
[5]   The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders [J].
Anton, Raymond F. ;
Litten, Raye Z. ;
Falk, Daniel E. ;
Palumbo, Joseph M. ;
Bartus, Raymond T. ;
Robinson, Rebecca L. ;
Kranzler, Henry R. ;
Kosten, Thomas R. ;
Meyer, Roger E. ;
O'Brien, Charles P. ;
Mann, Karl ;
Meulien, Didier .
NEUROPSYCHOPHARMACOLOGY, 2012, 37 (02) :402-411
[6]   Combined pharmacotherapies and behavioral interventions for alcohol dependence - The COMBINE study: A randomized controlled trial [J].
Anton, RF ;
O'Malley, SS ;
Ciraulo, DA ;
Cisler, RA ;
Couper, D ;
Donovan, DM ;
Gastfriend, DR ;
Hosking, JD ;
Johnson, BA ;
LoCastro, JS ;
Longabaugh, R ;
Mason, BJ ;
Mattson, ME ;
Miller, WR ;
Pettinati, HM ;
Randall, CL ;
Swift, R ;
Weiss, RD ;
Williams, LD ;
Zweben, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (17) :2003-2017
[7]   Clinical Relevance of As-Needed Treatment with Nalmefene in Alcohol-Dependent Patients [J].
Aubin, Henri-Jean ;
Reimer, Jens ;
Nutt, David J. ;
Bladstrom, Anna ;
Torup, Lars ;
Francois, Clement ;
Chick, Jonathan .
EUROPEAN ADDICTION RESEARCH, 2015, 21 (03) :160-168
[8]   Acceptance of Non-Abstinence Goals by Addiction Professionals in the United States [J].
Davis, Alan K. ;
Rosenberg, Harold .
PSYCHOLOGY OF ADDICTIVE BEHAVIORS, 2013, 27 (04) :1102-1109
[9]   Predictors of Pretreatment Commitment to Abstinence: Results from the COMBINE Study [J].
DeMartini, Kelly S. ;
Devine, Eric G. ;
DiClemente, Carlo C. ;
Martin, Daniel J. ;
Ray, Lara A. ;
O'Malley, Stephanie S. .
JOURNAL OF STUDIES ON ALCOHOL AND DRUGS, 2014, 75 (03) :438-446
[10]   Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials A Secondary Analysis of 3 Randomized Clinical Trials [J].
Falk, Daniel E. ;
O'Malley, Stephanie S. ;
Witkiewitz, Katie ;
Anton, Raymond F. ;
Litten, Raye Z. ;
Slater, Megan ;
Kranzler, Henry R. ;
Mann, Karl F. ;
Hasin, Deborah S. ;
Johnson, Bankole ;
Meulien, Didier ;
Ryan, Megan ;
Fertig, Joanne ;
Isenberg, Keith ;
McCann, David ;
Meyer, Roger E. ;
O'Brien, Charles ;
Silverman, Bernard ;
Trinquet, Francoise ;
Zakine, Benjamin ;
Aubin, Henri-Jean ;
Ramey, Tanya .
JAMA PSYCHIATRY, 2019, 76 (04) :374-381